GS-9695 and GS-9822 are next-generation noncatalytic site integrase inhibitors (NCINIs) with significantly improved potency against human immunodeficiency virus compared with previous drugs such as BI-224436. These data provide useful insights to guide discovery and development of NCINIs, related compounds, and zwitterions.